Home Administrative Billing & Reimbursement Health and Wellness Medical PEAR portal Pharmacy Products Quality Management

​​​COVID-19 tests for public health screening and surveillance are not covered

March 1, 2023

​As was previously communicated in our policy news article, Testing for SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)), AmeriHealth HMO, Inc., AmeriHealth Insurance Company of New Jersey, and AmeriHealth Administrators do not cover COVID-19 testing when the primary purpose of this testing is for public health screening and/or surveillance. This includes tests using pooling methodologies or any others with a current U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA).

As stated in Testing for SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)):

  • Scree​ning tests for SARS-CoV-2 are intended to identify occurrence of COVID-19 at the individual level even if there is no reason to suspect infection or COVID-19 exposure. The Centers for Disease Control and Prevention (CDC) includes examples of screening such as:
    • Testing employees in a workplace setting
    • Testing students, faculty, and staff in a school or university setting
    • Testing a person before or after travel
    • Testing at home for someone who does not have symptoms associated with COVID-19 and no known exposures to someone with COVID-19
  • Public health surveillance for SARS-CoV-2 includes ongoing systematic activities, including collection, analysis, and interpretation of health-related data that are essential to planning, implementing, and evaluating public health practice. An example of surveillance testing is a plan developed by a state public health department to randomly select and sample a percentage of all individuals in a city on a rolling basis to assess local infection rates and trends.

For example, the following ICD-10 screening codes, not an all-inclusive list, are not covered for COVID-19 testing:

  • Z11.59: Encounter for screening for other viral diseases
  • Z11.52: Encounter for screening for COVID-19
  • Z11.8: Encounter for screening for other infectious and parasitic diseases
  • Z11.9: Encounter for screening for infectious and parasitic diseases, unspecified
  • Z13.9: Encounter for screening, unspecified

For additional information on COVID-19 diagnostic, screening, and public health surveillance testing, please review the policy news article, Testing for SARS-CoV-2 (Coronavirus Disease 2019 (COVID-19)), which can be found in the News and Announcements section of the Medical and Claim Payment Policy Portal:


This content was prepared for the Provider News Center and may not be reproduced in any way without the express written permission of AmeriHealth, AmeriHealth HMO, Inc., AmeriHealth Insurance Company of New Jersey.
© 2023 AmeriHealth Site Map        Anti-Fraud        Privacy Policy        Legal        Disclaimer